TB-500: Recovery and Reported Doses
Recovery, movement and training
People look into TB-500 hoping to ease tendon or muscle problems and get back to training. Others want to know whether it adds anything to BPC-157.
Reliable human benefits remain uncertain. The name can also refer to different peptides, so a study or dose for one product may not apply to another.
The recovery goal
Getting back to what you doA better-feeling injury is one part of the picture.
- Symptoms Less discomfort
- Function Easier movement
- Activity Tolerating training
A reported course: initial and maintenance phases
The amount, frequency and duration below describe one person’s self-reported course. This is a reported example, not a studied, safe or recommended regimen.
Per-injection amount versus weekly total
| In this report | Initial phase | Later phase |
|---|---|---|
| Amount each time | 2.5 mg | 2.5 mg |
| Frequency | Twice weekly | Once weekly |
| Total per week | 5 mg | 2.5 mg |
| Reported weeks | Weeks 1–4 | Weeks 5–13 |
“Loading” and “maintenance” describe the change in frequency here. They do not establish that everyone needs either phase. Other sources describe different courses; thirteen weeks is this report’s duration, not a healing deadline or a safe maximum.
What changes are people hoping to notice?
Think in concrete tasks: walking upstairs, reaching overhead or tolerating the same rehabilitation exercise. Those changes are easier to compare than a general feeling of “better recovery.”
Reports of relief also vary in whether the improvement lasts. A better-feeling shoulder or knee is encouraging, but pain, tissue repair and readiness to train are different outcomes. The BPC-157 guide explains how to assess symptoms and function together while keeping rehabilitation and other changes in view.
TB-500 vs BPC-157
The pairing adds another ingredient, expense and uncertainty. Only four people in the small human knee-pain report received BPC-157 plus thymosin beta-4; it did not establish a better result from adding the second peptide.
“BPC for one injury, TB-500 for the whole body” is a convenient marketing story, not a demonstrated human comparison. Nor is TB-500 an established substitute when BPC-157 has not helped. See the BPC-157 versus TB-500 comparison for the differences that matter.
Why do daily and weekly schedules both appear?
People disagree about whether a short time in blood should mean frequent injections or whether effects might last longer. The argument cannot be settled by an assumed half-life: FDA found no human pharmacokinetic study for the TB-500 fragment products it assessed. FDA review.
The TB-500 compound page shows the scope of the site’s approximate curve. It cannot choose an effective schedule or tell you when an injury has finished healing.
Check which TB-500 the source means
The name on the vial can hide a meaningful difference
| Compare | Full thymosin beta-4 | TB-500 fragment |
|---|---|---|
| Size | 43 amino acids | 7 amino acids, with an acetyl group |
| Human research cited here | IV safety and local skin-ulcer studies | No established human injury-recovery result |
The FDA identity review explains the distinction. A product called TB-500 should not inherit every claim made about full-length thymosin beta-4.
Thymosin beta-4’s roles in cell movement and wound repair explain the research interest. Human work includes IV safety testing and a topical skin-ulcer study. Neither establishes that a similarly named injection repairs a sports injury, or that a fragment reproduces the full peptide’s effects.
Side effects
The trade-offs include uncertain benefit, incomplete long-term safety information and uncertain product contents. FDA identifies possible immune reactions and peptide impurities for the fragment; the absence of reported problems does not establish a side-effect rate or safety. FDA assessment.
Injection also introduces preparation and sterility concerns. A purity percentage cannot answer all of those questions. The stacking guide covers why changing several compounds together makes reactions harder to interpret.
Frequently asked questions
Is TB-500 the same as thymosin alpha-1?
No. Thymosin alpha-1 is a different peptide. Similar names do not establish the same uses or interchangeable amounts.
Can TB-500 be taken orally?
The cited research does not establish oral treatment with the fragment for injury recovery. An injected amount cannot simply be reused as an equivalent capsule amount.
How long does a TB-500 cycle last?
Reported courses vary. The example above runs thirteen weeks with a frequency change after four weeks. That is one report, not an established human recovery course.
Does TB-500 show on a drug test?
The 2026 WADA list prohibits thymosin beta-4 and derivatives such as TB-500. This guide provides no reliable detection window; elimination half-life cannot promise a negative test.
Can I stack TB-500 with BPC-157?
People do report the combination, but a better recovery result and a safe combined regimen have not been established. Read the comparison guide before treating the pairing as proven complementary treatment.
Sources
Product identity and study details
- FDA’s July 2026 briefing identifies full thymosin beta-4 as 43 amino acids and TB-500 as the N-acetylated seven-residue fragment Ac-LKKTETQ. An acetate salt is a separate chemical detail from that N-terminal acetyl group. The document also explains inconsistent commercial naming and the limits of human evidence.
- Ruff et al. studied intravenous full-length thymosin beta-4 in 40 healthy volunteers, including repeated exposure for 14 days. It assessed safety and drug levels, not tendon-injury recovery.
- The 73-person ulcer study tested a local full-length preparation for venous skin ulcers. Its route and treatment target differ from the reported injection course.
- Fragment-metabolism research used laboratory systems and rats. A cell wound-assay signal concerned a breakdown product; it was not a human healing result.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.